



the unified voice of cardiovascular researchers, industry and peak bodies throughout the country. The ACvA's structure, goals and commitment to building the capacity and capability of the sector means that the very best research leaders and teams can be strategically placed to work as closely as possible with the health system and industry towards prioritised health problems, providing greater value for money from government investments and greater impact for the Australian community and economy.

*"The Australian Cardiovascular Alliance is pleased to partner with ClinTrial Refer utilising its digital footprint to increase the visibility, recruitment and knowledge management of our current clinical trials in cardiology, as we aim to tackle one of our biggest health burdens."*

Professor Gemma Figtree, President - ACvA.



Six strategic flagships have been established to help cut across major clinical challenges in cardiovascular disease and bring together the entire cardiovascular research community through a whole-of-nation approach along a bi-directional translational pipeline. This ensures that Australian cardiovascular researchers are aligned to the most urgent clinical challenges and that discoveries and innovative approaches to care are translated to the patient's bedside.

The ACvA is a unique model in the Australian landscape and provides a strong framework to drive international success and collaboration. The ACvA welcomes like-minded researchers, clinicians, peak bodies and industry from across the globe to collaborate with them in achieving their vision.

---

## **ClinTrial Refer at ARCS Australia Conference 2021**

It was delightful to be able to meet in person with so many of our clinical research and industry colleagues and health consumer representatives at the 3-day ARCS Australia 2021 Conference in Sydney at the ICC Darling Harbour on 7-9 June. Organising a successful large scale conference in the challenging and ever changing times of the COVID-19 pandemic was a major achievement for ARCS Australia CEO Shanny Dyer and her team. Despite the sudden June lockdown in Melbourne meaning that most Victorians were unable to travel, over 1200 delegates came together for three days of amazing presentations and networking opportunities. Victorian and international speakers joined the sessions by Zoom in a very successful hybrid conference model. After 14 months of Zoom meetings and WFH the excitement of being able to reconnect face-to-face with colleagues from across the sector was palpable. It was very enjoyable to meet so many of our ClinTrial Refer users in real life at the ClinTrial Refer exhibition stand and in the educational sessions.

We would particularly like to congratulate our colleagues at NSW Health Pathology who won the MPT Sector award for Innovation in an Organisation for their rapid development and implementation of an accurate, timely and sensitive method to generate the SARS-CoV-2 genomic sequence from infected individuals across NSW and subsequently determine the extent of genomic diversity contained within the SARS-CoV-2 genome from the individual host.



## Clinical Trial Spotlight: The IMAGE Trial



Skin cancer is Australia's most common and most expensive cancer in terms of burden on the healthcare system. Given the magnitude of healthcare spending, the Australian Government needs better evidence to make informed decisions. Should Total Body Photography (TBP) be subsidised by Medicare? The IMAGE trial aims to answer that question and, in doing so, potentially reduce the number of unnecessary 'just in case' biopsies carried out in Australia.



Total body photography provides a baseline record of every mole in high risk patients so doctors can track any changes in the appearance of moles which may be melanoma. Patients at high risk of developing a second primary invasive melanoma are most likely to benefit from melanoma surveillance photography which comprises total body photography and digital dermoscopy.

Sponsored by Monash University and coordinated by Melanoma and Skin Cancer Trials, the IMAGE trial aims to recruit 680 participants across sites in Queensland, Victoria and New South Wales. Open and recruiting participants include:

- Victorian Melanoma Service, The Alfred, VIC ([ymstrials@alfred.org.au](mailto:ymstrials@alfred.org.au))
- Skin Health Institute, Melbourne VIC ([schivers@skinhealthinstitute.org.au](mailto:schivers@skinhealthinstitute.org.au))
- Bendigo Health Cancer Centre, Bendigo VIC ([nmcphee@bendigohealth.org.au](mailto:nmcphee@bendigohealth.org.au))
- UQ-Diamantina Institute, Brisbane QLD ([k.nufer@uq.edu.au](mailto:k.nufer@uq.edu.au))

Several more sites throughout Victoria, New South Wales and Queensland will begin recruiting participants over the coming months.

- Patients within 6 months of diagnosis of their first primary melanoma and moderate/many naevi are eligible.
- Patients will be randomised to receive melanoma surveillance photography or no melanoma surveillance photography. Images will be provided to patients to take to follow-up visits with their usual doctor. All participants will be offered 3D TBP at the end of the trial (24 months).

Patients who have been under surveillance with total body photography prior to diagnosis are eligible for a planned sub-study comparing Breslow thickness of the primary melanoma and excision rates prior to their melanoma diagnosis.

This exciting and practice-changing trial is led by A/Prof Victoria Mar, Director of the Victorian Melanoma Service at The Alfred and Adjunct Professor at the School of Public Health and Preventive Medicine, Monash University.

For more information, please visit <https://www.masc.org.au/recruiting-trials/> or email [image@masc.org.au](mailto:image@masc.org.au)

View the trial details and recruiting locations on ClinTrial Refer [here](#).

---

## New journal article on improving clinical trial recruitment

Participants are integral to the success of any clinical research study, yet participant recruitment into clinical trials poses ongoing and complex challenges. It is widely recognised that clinical trial sites often find it difficult to meet recruitment goals, both in terms of accrual targets and timelines. This can impact the validity of trials or cause major delays for research. There are very few frameworks available to clinical trial sites to improve recruitment. The Australian CT:IQ GREET project (Guidance to Recruitment: Examining Experiences at clinical Trial sites) sought to identify barriers to recruitment and produce formal guidance to optimise recruitment outcomes. The results of the project have recently been published.

CT:IQ is a collaborative group of stakeholders invested in improving the impact and quality of clinical trials in Australia. ClinTrial Refer is a member of the CT:IQ steering committee and Christine Zahren, our Business Development Manager, was an active part of the GREET project team and is the lead author on the recently published article from the project. The article in the peer-reviewed journal *Clinical Trials* is now freely available [here](#). ClinTrial Refer would like to congratulate the GREET project team members involved in the publication including Sonia Harvey, Leanne Weekes, Charlotte Bradshaw, Radhika Butala, John Andrews and Sally O'Callaghan and indeed all the team for their collaboration on this project.


As we try to navigate our way through a world that continues to be impacted by the COVID-19 pandemic, many new and ongoing clinical trials will be disrupted. Clinical trial sponsors, researchers and trial sites may be asked to postpone planned trials as well as trials that are actively recruiting or in the start-up phase. In addition to the journal article, the GREET site recruitment guide, which contains recommendations, tools and resources, can be accessed via the [CT:IQ GREET project website](#) as either a PDF document or an online learning platform called Teachable.




## App Focus - How to tell us if something needs updating

The ClinTrial Refer research community is constantly working to add information about new trials that are available and to update the information for trials that are already in the database, such as the trial locations that are currently recruiting and exactly who to contact about the trial. You can help us if you find any information that needs to be updated by notifying us directly from the ClinTrial Refer App. You can either send us a quick message from the main menu in the ClinTrial Refer App, or from within a specific trial and we can update the available information for everyone to see.

You can notify us about information that needs to be changed from the ClinTrial Refer App main menu. Just click on **Report an error** and complete the pop-up form and send.



Or you can notify us from within a specific trial, just click on **...** at the top of the ClinTrial Refer screen. Click on **Report Issue** and complete the popup form and press send.



## Clinical Trial Spotlight: Do you have depression?

# Do you have Depression?

Help us understand why people respond differently to depression treatments.

### EEG (electroencephalogram)

A non-invasive EEG will be used to record your brainwaves. The recording will be before you start treatment and will be repeated twice throughout the study

### ASSESSMENT

You will be required to:

- take a daily dose of a locally approved antidepressant medication for 8 weeks, with an optional follow-up visit after 16 weeks
- fill out a series of questionnaires at each research appointment, and our clinician will conduct an interview
- provide a saliva and blood sample for genetics test

Your **de-identified** information will be used in combination with all other data collected during the study.



### BENEFITS



Reimbursement- You will be compensated for your time and participation.



Fitbit - We provide a Fitbit for you to wear throughout the study and which you keep at the end of the study.

### BASIC QUALIFICATIONS

18 to <75 years of age

Not pregnant

Not breastfeeding

Fluent in English

Able to provide informed consent

Additional eligibility criteria may apply

### INTERESTED?

Contact **Ana Rita Barreiros** (Clinical Research Coordinator) on +61 (2) 8627 3319 or [ana.barreiros@sydney.edu.au](mailto:ana.barreiros@sydney.edu.au) for more information.

V3 23-Feb-2021

View the trial details and recruiting locations on ClinTrial Refer [here](#).

---

## Do you have something to share?

Share your story if you have taken part in a clinical trial or supported someone through a trial. Your stories and thoughts are important to us and can be a great encouragement to others. If you'd like to share a clinical trial story please email us at [admin@clintrialreferapp.com](mailto:admin@clintrialreferapp.com). We'd love to hear from you.



Facebook Twitter LinkedIn Website



### ADDRESS

ClinTrial Refer c/o Ground Floor,  
W R Pitney Building, St George Hospital,  
Gray Street, KOGARAH 2217  
Australia

### EMAIL

[www.clintrialrefer.org.au/](http://www.clintrialrefer.org.au/)

[admin@clintrialreferapp.com](mailto:admin@clintrialreferapp.com)

[Unsubscribe](#)

Copyright © \*2019\* \*ClinTrial Refer\*, All rights reserved.

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

ClinTrialRefer · St George Hospital · Gray Street · Kogarah, Nsw 2017 · Australia